Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


04.02.2019

1 Am J Clin Exp Urol
1 Ann Diagn Pathol
3 BJU Int
1 BMC Urol
1 Cancer Biomark
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Immunol Res
1 Cell Death Differ
1 Clin Genitourin Cancer
1 Curr Urol Rep
1 Eur J Cancer
2 Exp Ther Med
1 Expert Opin Pharmacother
1 Free Radic Biol Med
1 Front Oncol
1 Glycobiology
1 Indian J Pathol Microbiol
1 Int J Environ Res Public Health
2 Int J Urol
1 J Infect Chemother
1 J Med Imaging Radiat Oncol
3 J Urol
1 Mater Sci Eng C Mater Biol Appl
1 Medicine (Baltimore)
1 Nat Protoc
1 PLoS One
1 Scand J Urol
1 Spectrochim Acta A Mol Biomol Spectrosc
1 Target Oncol
15 Transl Androl Urol
2 Urol Int
3 Urol Oncol
1 Vet Radiol Ultrasound
1 Virchows Arch
1 World J Surg Oncol
1 World J Urol
1 Zhonghua Zhong Liu Za Zhi


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Exp Urol

  1. RAVEN PA, D'Costa NM, Moskalev I, Tan Z, et al
    Development of a murine intravesical orthotopic human bladder cancer (mio-hBC) model.
    Am J Clin Exp Urol. 2018;6:245-259.
    PubMed     Text format     Abstract available


    Ann Diagn Pathol

  2. ABDELRAHMAN AE, Rashed HE, Elkady E, Elsebai EA, et al
    Fatty acid synthase, Her2/neu, and E2F1 as prognostic markers of progression in non-muscle invasive bladder cancer.
    Ann Diagn Pathol. 2019;39:42-52.
    PubMed     Text format     Abstract available


    BJU Int

  3. JEFFERIES ER, Cresswell J, McGrath JS, Miller C, et al
    Open radical cystectomy in England: the current standard of care - an analysis of the British Association of Urological Surgeons (BAUS) cystectomy audit and Hospital Episodes Statistics (HES) data.
    BJU Int. 2018;121:880-885.
    PubMed     Text format     Abstract available

  4. MMEJE CO, Benson CR, Nogueras-Gonzalez GM, Jayaratna IS, et al
    Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy.
    BJU Int. 2018;122:89-98.
    PubMed     Text format     Abstract available

  5. TAN WS, Teo CH, Chan D, Heinrich M, et al
    Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.
    BJU Int. 2019 Jan 29. doi: 10.1111/bju.14690.
    PubMed     Text format     Abstract available


    BMC Urol

  6. HA YS, Kim SW, Chun SY, Chung JW, et al
    Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.
    BMC Urol. 2019;19:10.
    PubMed     Text format     Abstract available


    Cancer Biomark

  7. SHI S, Tian B
    Identification of biomarkers associated with progression and prognosis in bladder cancer via co-expression analysis.
    Cancer Biomark. 2019 Jan 18. pii: CBM181940. doi: 10.3233/CBM-181940.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  8. ANDREW AS, Karagas MR, Schroeck FR, Marsit CJ, et al
    MicroRNA dysregulation and non-muscle invasive bladder cancer prognosis.
    Cancer Epidemiol Biomarkers Prev. 2019 Jan 30. pii: 1055-9965.EPI-18-0884.
    PubMed     Text format     Abstract available


    Cancer Immunol Res

  9. DOMINGOS-PEREIRA S, Sathiyanadan K, La Rosa S, Polak L, et al
    Intravesical Ty21a vaccine promotes dendritic cells and T cell-mediated tumor regression in the MB49 bladder cancer model.
    Cancer Immunol Res. 2019 Jan 29. pii: 2326-6066.CIR-18-0671.
    PubMed     Text format     Abstract available


    Cell Death Differ

  10. RAMAKRISHNAN S, Granger V, Rak M, Hu Q, et al
    Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
    Cell Death Differ. 2019 Jan 28. pii: 10.1038/s41418-019-0278.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  11. JIANG DM, Jiang H, Chung PWM, Zlotta AR, et al
    Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019;17:38-45.
    PubMed     Text format     Abstract available


    Curr Urol Rep

  12. LOH-DOYLE JC
    Penile Implant Considerations in the Bladder Cancer Survivor.
    Curr Urol Rep. 2019;20:7.
    PubMed     Text format     Abstract available


    Eur J Cancer

  13. NECCHI A, Raggi D, Giannatempo P, Alessi A, et al
    Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
    Eur J Cancer. 2018;96:128-130.
    PubMed     Text format    


    Exp Ther Med

  14. WANG Y, Xu Z, Wang X
    miRNA-373 promotes urinary bladder cancer cell proliferation, migration and invasion through upregulating epidermal growth factor receptor.
    Exp Ther Med. 2019;17:1190-1195.
    PubMed     Text format     Abstract available

  15. CHEN L, Long Y, Han Z, Yuan Z, et al
    MicroRNA-101 inhibits cell migration and invasion in bladder cancer via targeting FZD4.
    Exp Ther Med. 2019;17:1476-1485.
    PubMed     Text format     Abstract available


    Expert Opin Pharmacother

  16. LALANI AA, Sonpavde GP
    Systemic treatments for metastatic urothelial carcinoma.
    Expert Opin Pharmacother. 2019;20:201-208.
    PubMed     Text format     Abstract available


    Free Radic Biol Med

  17. WHONGSIRI P, Pimratana C, Wijitsettakul U, Sanpavat A, et al
    Oxidative stress and LINE-1 reactivation in bladder cancer are epigenetically linked through active chromatin formation.
    Free Radic Biol Med. 2019 Jan 28. pii: S0891-5849(18)32321.
    PubMed     Text format     Abstract available


    Front Oncol

  18. MENG XY, Shi MJ, Zeng ZH, Chen C, et al
    The Role of COL5A2 in Patients With Muscle-Invasive Bladder Cancer: A Bioinformatics Analysis of Public Datasets Involving 787 Subjects and 29 Cell Lines.
    Front Oncol. 2019;8:659.
    PubMed     Text format     Abstract available


    Glycobiology

  19. VISNJAR T, Romih R, Zupancic D
    Lectins as possible tools for improved urinary bladder cancer management.
    Glycobiology. 2019 Jan 25. pii: 5301307. doi: 10.1093.
    PubMed     Text format     Abstract available


    Indian J Pathol Microbiol

  20. ADHYA AK, Pradhan MR
    Ectopic prostatic tissue presenting as a mucosal tumor in urinary bladder.
    Indian J Pathol Microbiol. 2018;61:452-453.
    PubMed     Text format    


    Int J Environ Res Public Health

  21. LI CY, Dai YX, Chen YJ, Chu SY, et al
    Cancer Risks in Vitiligo Patients: A Nationwide Population-Based Study in Taiwan.
    Int J Environ Res Public Health. 2018;15.
    PubMed     Text format     Abstract available


    Int J Urol

  22. KOIE T, Ohyama C, Makiyama K, Shimazui T, et al
    Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13900.
    PubMed     Text format     Abstract available

  23. TEISHIMA J, Matsubara A
    Editorial Comment to Utility of robot-assisted radical cystectomy with intracorporeal urinary diversion for muscle-invasive bladder cancer.
    Int J Urol. 2019 Jan 28. doi: 10.1111/iju.13906.
    PubMed     Text format    


    J Infect Chemother

  24. MURAKAMI M, Kiyota H, Kasai K, Bando S, et al
    Antimicrobial prophylaxis for transurethral resection of bladder tumor: A retrospective comparison of preoperative single-dose administration of piperacillin and tazobactam/piperacillin.
    J Infect Chemother. 2018;24:954-957.
    PubMed     Text format     Abstract available


    J Med Imaging Radiat Oncol

  25. KONG V, Taylor A, Chung P, Rosewall T, et al
    Evaluation of resource burden for bladder adaptive strategies: A timing study.
    J Med Imaging Radiat Oncol. 2018;62:861-865.
    PubMed     Text format     Abstract available


    J Urol

  26. MEEKS JJ, Glaser AP
    Editorial Comment.
    J Urol. 2018;200:60.
    PubMed     Text format    

  27. FILSON CP
    Editorial Comment.
    J Urol. 2018;200:59.
    PubMed     Text format    

  28. HAIFLER M
    Editorial Comment.
    J Urol. 2018;200:59-60.
    PubMed     Text format    


    Mater Sci Eng C Mater Biol Appl

  29. CHO SK, Su LJ, Mao C, Wolenski CD, et al
    Multifunctional nanoclusters of NaYF4:Yb(3+),Er(3+) upconversion nanoparticle and gold nanorod for simultaneous imaging and targeted chemotherapy of bladder cancer.
    Mater Sci Eng C Mater Biol Appl. 2019;97:784-792.
    PubMed     Text format     Abstract available


    Medicine (Baltimore)

  30. ZHOU J, Yang C, Lu Z, Zhang L, et al
    Primary urothelial carcinoma of the prostate: A rare case report.
    Medicine (Baltimore). 2019;98:e14155.
    PubMed     Text format     Abstract available


    Nat Protoc

  31. LORENZATTI HILES G, Cates AL, El-Sawy L, Day KC, et al
    A surgical orthotopic approach for studying the invasive progression of human bladder cancer.
    Nat Protoc. 2019 Jan 25. pii: 10.1038/s41596-018-0112.
    PubMed     Text format     Abstract available


    PLoS One

  32. BOSSCHIETER J, Bach S, Bijnsdorp IV, Segerink LI, et al
    A protocol for urine collection and storage prior to DNA methylation analysis.
    PLoS One. 2018;13:e0200906.
    PubMed     Text format     Abstract available


    Scand J Urol

  33. BURGER M
    Editorial Commentary on Gregers et al.
    Scand J Urol. 2018;52:199.
    PubMed     Text format    


    Spectrochim Acta A Mol Biomol Spectrosc

  34. GU YQ, Shen WY, Zhou Y, Chen SF, et al
    A pyrazolopyrimidine based fluorescent probe for the detection of Cu(2+) and Ni(2+) and its application in living cells.
    Spectrochim Acta A Mol Biomol Spectrosc. 2019;209:141-149.
    PubMed     Text format     Abstract available


    Target Oncol

  35. FONT A, Luque R, Villa JC, Domenech M, et al
    The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG).
    Target Oncol. 2019 Jan 29. pii: 10.1007/s11523-019-00619.
    PubMed     Text format     Abstract available


    Transl Androl Urol

  36. PATHAK RA, Hemal AK
    Frailty and sarcopenia impact surgical and oncologic outcomes after radical cystectomy in patients with bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  37. KAAG MG, Raman JD
    Sarcopenia is a reliable predictor of outcomes following radical cystectomy for bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  38. PICHLER R, Loidl W, Pichler M
    High economic burden of immunotherapy underlines the need of predictive biomarkers for the individual therapy algorithm in metastatic bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  39. BIELLI P, Di Stasi SM, Sette C
    The emerging role of PTBP1 in human cancer: novel prognostic factor in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  40. NIEGISCH G
    Does robotic radical cystectomy impede oncological outcome in bladder cancer patients?
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  41. SORIA F, Shariat SF
    Biomarkers for the prediction of oncologic outcomes in non-muscle invasive bladder cancer: state of affairs and new frontiers.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  42. BRODIE A, McCauley N, Cresswell J, Vasdev N, et al
    T1G3 bladder cancer, bacillus Calmette-Guerin and radical cystectomy: continued debate.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  43. VRIELING A
    The association of BMI with risk of recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  44. ROSSER CJ
    Nutritional implications for quality of life in bladder cancer survivors.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  45. OOSTERLINCK W, Decaestecker K
    An immediate intravesical instillation of mitomycin C is of benefit in all prognostic risk groups with non-muscle-invasive bladder cancers.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  46. DAL MORO F, Colicchia M
    Does obesity impact bladder cancer prognosis?-a long-lasting debate.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  47. LEE KH, Ku JH
    Targeting splicing factors as molecular non-muscle invasive bladder cancer predictors.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  48. MAHENDRAN R
    Do we have all the facts to determine the impact of bacillus Calmette-Guerin therapy on bladder cancer?
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  49. AJIB K, Kulkarni GS
    Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    

  50. BATURA D
    Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer.
    Transl Androl Urol. 2018;7.
    PubMed     Text format    


    Urol Int

  51. MOSCHINI M, Zamboni S, Mattei A, Baumeister P, et al
    Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification?
    Urol Int. 2019 Jan 29:1-8. doi: 10.1159/000493899.
    PubMed     Text format     Abstract available

  52. GROEBEN C, Koch R, Baunacke M, Borkowetz A, et al
    In-Hospital Outcomes after Radical Cystectomy for Bladder Cancer: Comparing National Trends in the United States and Germany from 2006 to 2014.
    Urol Int. 2019 Jan 30:1-9. doi: 10.1159/000496347.
    PubMed     Text format     Abstract available


    Urol Oncol

  53. MILLER R, Heinlen JE
    Reported rates of clostridium difficile following radical cystectomy in national datasets compared to individual institutions.
    Urol Oncol. 2018;36:526.
    PubMed     Text format     Abstract available

  54. MARTINI T, Heinkele J, Mayr R, Weis CA, et al
    Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.
    Urol Oncol. 2018;36:530.
    PubMed     Text format     Abstract available

  55. BLACK PC, Goebell PJ, Kamat AM, Nawroth R, et al
    Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series(1).
    Urol Oncol. 2019 Jan 22. pii: S1078-1439(19)30003.
    PubMed     Text format     Abstract available


    Vet Radiol Ultrasound

  56. LEFFLER AJ, Hostnik ET, Warry EE, Habing GG, et al
    Canine urinary bladder transitional cell carcinoma tumor volume is dependent on imaging modality and measurement technique.
    Vet Radiol Ultrasound. 2018;59:767-776.
    PubMed     Text format     Abstract available


    Virchows Arch

  57. RIVA G, Mian C, Luchini C, Girolami I, et al
    Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis.
    Virchows Arch. 2019;474:13-20.
    PubMed     Text format     Abstract available


    World J Surg Oncol

  58. TONG S, Yang Z, Zu X, Li Y, et al
    Anterior versus posterior approach laparoscopic radical cystectomy: a retrospective analysis.
    World J Surg Oncol. 2019;17:9.
    PubMed     Text format     Abstract available


    World J Urol

  59. LEOW JJ, Bedke J, Chamie K, Collins JW, et al
    SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
    World J Urol. 2019 Jan 25. pii: 10.1007/s00345-018-2606.
    PubMed     Text format     Abstract available


    Zhonghua Zhong Liu Za Zhi


  60. [Expert consensus on treatment of intravesical therapy in non-muscle invasive bladder cancer].
    Zhonghua Zhong Liu Za Zhi. 2019;41:42-45.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: